Background: Hypomagnesemia with secondary hypocalcemia is due to disturbed renal and intestinal magnesium (Mg2+) (re)absorption. The underlying defect is a mutation in the transient receptor potential melastatin type 6 (TRPM6), a Mg2+-permeable ion channel expressed in the kidney and intestine. Our aim was to characterize homozygous (–/–) and heterozygous (+/–) TRPM6 knockout mice with respect to Mg2+ homeostasis. Methods: TRPM6+/– mice were bred on a normal (0.19% wt/wt Mg2+) and high (0.48% wt/wt Mg2+) Mg2+ diet. In the offspring, 24-hour urinary Mg2+ and calcium excretion as well as serum concentrations of both were determined. TRPM6 mRNA expression in the kidney and colon was measured. Results: On the regular diet, 30% of the offspring were TRPM6 wild-type (+/+), 70% were TRPM6+/–, and none were TRPM6–/–. The genotypic distribution of the litters remained the same on the 0.48% Mg2+ diet. In TRPM6+/– mice on both diets, serum Mg2+ levels were significantly lower, and renal and intestinal TRPM6 mRNA expression was reduced. Urinary Mg2+ excretion was unaffected. Conclusions: Homozygous TRPM6 deletion is embryonic lethal in mice. Heterozygous deletion of TRPM6 results in a mild hypomagnesemia. The Mg2+-enriched diet could not compensate for either embryonic lethality or hypomagnesemia caused by TRPM6 deficiency.

1.
Flatman PW: Magnesium transport across cell membranes. J Membr Biol 1984;80:1–14.
2.
Quamme GA, Dirks JH: Magnesium transport in the nephron. Am J Physiol 1980;239:F393–F401.
3.
Fine KD, Santa Ana CA, Porter JL, Fordtran JS: Intestinal absorption of magnesium from food and supplements. J Clin Invest 1991;88:396–402.
4.
de Rouffignac C, Quamme G: Renal magnesium handling and its hormonal control. Physiol Rev 1994;74:305–322.
5.
Paunier L, Radde IC, Kooh SW, Conen PE, Fraser D: Primary hypomagnesemia with secondary hypocalcemia in an infant. Pediatrics 1968;41:385–402.
6.
Lombeck I, Ritzl F, Schnippering HG, Michael H, Bremer HJ, Feinendegen LE, Kosenow W: Primary hypomagnesemia. 1. Absorption studies. Z Kinderheilkd 1975;118:249–258.
7.
Milla PJ, Aggett PJ, Wolff OH, Harries JT: Studies in primary hypomagnesaemia: evidence for defective carrier-mediated small intestinal transport of magnesium. Gut 1979;20:1028–1033.
8.
Walder RY, Landau D, Meyer P, Shalev H, Tsolia M, Borochowitz Z, Boettger MB, Beck GE, Englehardt RK, Carmi R, Sheffield VC: Mutation of TRPM6 causes familial hypomagnesemia with secondary hypocalcemia. Nat Genet 2002;31:171–174.
9.
Anast CS, Mohs JM, Kaplan SL, Burns TW: Evidence for parathyroid failure in magnesium deficiency. Science 1972;177:606–608.
10.
Shalev H, Phillip M, Galil A, Carmi R, Landau D: Clinical presentation and outcome in primary familial hypomagnesaemia. Arch Dis Child 1998;78:127–130.
11.
Schlingmann KP, Sassen MC, Weber S, Pechmann U, Kusch K, Pelken L, Lotan D, Syrrou M, Prebble JJ, Cole DE, Metzger DL, Rahman S, Tajima T, Shu SG, Waldegger S, Seyberth HW, Konrad M: Novel TRPM6 mutations in 21 families with primary hypomagnesemia and secondary hypocalcemia. J Am Soc Nephrol 2005;16:3061–3069.
12.
Schlingmann KP, Weber S, Peters M, Niemann Nejsum L, Vitzthum H, Klingel K, Kratz M, Haddad E, Ristoff E, Dinour D, Syrrou M, Nielsen S, Sassen M, Waldegger S, Seyberth HW, Konrad M: Hypomagnesemia with secondary hypocalcemia is caused by mutations in TRPM6, a new member of the TRPM gene family. Nat Genet 2002;31:166–170.
13.
Voets T, Nilius B, Hoefs S, van der Kemp AW, Droogmans G, Bindels RJ, Hoenderop JG: TRPM6 forms the Mg2+ influx channel involved in intestinal and renal Mg2+ absorption. J Biol Chem 2004;279:19–25.
14.
Riazanova LV, Pavur KS, Petrov AN, Dorovkov MV, Riazanov AG: Novel type of signaling molecules: protein kinases covalently linked to ion channels. Mol Biol (Mosk) 2001;35:321–332.
15.
Nadler MJ, Hermosura MC, Inabe K, Perraud AL, Zhu Q, Stokes AJ, Kurosaki T, Kinet JP, Penner R, Scharenberg AM, Fleig A: LTRPC7 is a Mg.ATP-regulated divalent cation channel required for cell viability. Nature 2001;411:590–595.
16.
Chubanov V, Waldegger S, Mederos y Schnitzler M, Vitzthum H, Sassen MC, Seyberth HW, Konrad M, Gudermann T: Disruption of TRPM6/TRPM7 complex formation by a mutation in the TRPM6 gene causes hypomagnesemia with secondary hypocalcemia. Proc Natl Acad Sci USA 2004;101:2894–2899.
17.
Chubanov V, Schlingmann KP, Waring J, Heinzinger J, Kaske S, Waldegger S, Mederos y Schnitzler M, Gudermann T: Hypomagnesemia with secondary hypocalcemia due to a missense mutation in the putative pore-forming region of TRPM6. J Biol Chem 2007;282:7656–7667.
18.
Esteban-Oliva D, Pintos-Morell G, Konrad M: Long-term follow-up of a patient with primary hypomagnesaemia and secondary hypocalcaemia due to a novel TRPM6 mutation. Eur J Pediatr 2009;168:439–442.
19.
Groenestege WM, Hoenderop JG, van den Heuvel L, Knoers N, Bindels RJ: The epithelial Mg2+ channel transient receptor potential melastatin 6 is regulated by dietary Mg2+ content and estrogens. J Am Soc Nephrol 2006;17:1035–1043.
20.
Rondon LJ, Groenestege WM, Rayssiguier Y, Mazur A: Relationship between low magnesium status and TRPM6 expression in the kidney and large intestine. Am J Physiol Regul Integr Comp Physiol 2008;294:R2001–R2007.
21.
Groenestege WM, Thebault S, van der Wijst J, van den Berg D, Janssen R, Tejpar S, van den Heuvel LP, van Cutsem E, Hoenderop JG, Knoers NV, Bindels RJ: Impaired basolateral sorting of pro-EGF causes isolated recessive renal hypomagnesemia. J Clin Invest 2007;117:2260–2267.
22.
Thebault S, Alexander RT, Tiel Groenestege WM, Hoenderop JG, Bindels RJ: EGF increases TRPM6 activity and surface expression. J Am Soc Nephrol 2009;20:78–85.
23.
Glaudemans B, van der Wijst J, Scola RH, Lorenzoni PJ, Heister A, van der Kemp AW, Knoers NV, Hoenderop JG, Bindels RJ: A missense mutation in the Kv1.1 voltage-gated potassium channel-encoding gene KCNA1 is linked to human autosomal dominant hypomagnesemia. J Clin Invest 2009;119:936–942.
24.
Runnels LW, Yue L, Clapham DE: TRP-PLIK, a bifunctional protein with kinase and ion channel activities. Science 2001;291:1043–1047.
25.
Schmitz C, Perraud AL, Johnson CO, Inabe K, Smith MK, Penner R, Kurosaki T, Fleig A, Scharenberg AM: Regulation of vertebrate cellular Mg2+ homeostasis by TRPM7. Cell 2003;114:191–200.
26.
Elizondo MR, Arduini BL, Paulsen J, MacDonald EL, Sabel JL, Henion PD, Cornell RA, Parichy DM: Defective skeletogenesis with kidney stone formation in dwarf zebrafish mutant for TRPM7. Curr Biol 2005;15:667–671.
27.
Jin J, Desai BN, Navarro B, Donovan A, Andrews NC, Clapham DE: Deletion of TRPM7 disrupts embryonic development and thymopoiesis without altering Mg2+ homeostasis. Science 2008;322:756–760.
28.
Walder RY, Yang B, Stokes JB, Kirby PA, Cao X, Shi P, Searby CC, Husted RF, Sheffield VC: Mice defective in TRPM6 show embryonic mortality and neural tube defects. Hum Mol Genet 2009;18:4367–4375.
29.
Hoenderop JG, Muller D, Van Der Kemp AW, Hartog A, Suzuki M, Ishibashi K, Imai M, Sweep F, Willems PH, Van Os CH, Bindels RJ: Calcitriol controls the epithelial calcium channel in kidney. J Am Soc Nephrol 2001;12:1342–1349.
30.
Gu H, Marth JD, Orban PC, Mossmann H, Rajewsky K: Deletion of a DNA polymerase beta gene segment in T cells using cell type-specific gene targeting. Science 1994;265:103–106.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.